Familial lipoprotein lipase (LPL) deficiency is a rare genetic disorder accompanied by well-characterized manifestations. The phenotypic expression of heterozygous LPL deficiency has not been so clearly defined. We studied the pedigree of a proband known to be homozygous for a mutation resulting in nonfunctional LPL. Hybridization of DNA from 126 members with allele-specific probes detected 29 carriers of the mutant allele. Adipose tissue LPL activity, measured previously, was reduced by 50% in carriers, but did not reliably distinguish them from noncarriers. Carriers were prone to the expression of a form of familial hypertriglyceridemia characterized by increased plasma triglyceride, VLDL cholesterol and apolipoprotein B, and decreased LDL and HDL cholesterol concentrations. These manifestations were age modulated, with conspicuous differences between carriers and noncarriers observed only after age 40. Several noncarriers exhibited similar lipid abnormalities, but without the inverse relationship between VLDL cholesterol and LDL cholesterol noted among carriers. In addition to age and carrier status, the potentially reversible conditions, obesity, hyperinsulinemia and lipid-raising drug use were contributory. Thus heterozygous lipoprotein lipase deficiency, together with age-related influences, may account for a form of familial hypertriglyceridemia. (J. Clin. Invest.
Introduction
Familial hyperchylomicronemia (type I hyperlipoproteinemia) is a rare inherited disease due to complete or near-complete deficiency of lipoprotein lipase (LPL),' a triglyceride hydrolase responsible for the processing of the triglyceride-rich lipoproteins, chylomicrons, and VLDLs. Affected subjects classically present in infancy with fat intolerance, episodic ab-dominal pain with or without documented pancreatitis, eruptive xanthomatosis, severe hypertriglyceridemia, and fasting hyperchylomicronemia (1) (2) (3) . A clinically similar disorder occurs with inherited deficiency of the LPL cofactor, apo C-II (1, 4).
The inheritance of familial hyperchylomicronemia is characterized by the absence of vertical transmission, multiple affected siblings, frequent consanguinity, and reduced LPL activities in parents (1-8). These findings imply that LPL-deficient probands are often homozygous for a mutant LPL allele. Relatives of reported probands have had variable lipoprotein patterns. Parents have had either increased VLDL alone or entirely normal lipids and lipoproteins (1) . Other family members suspected of being heterozygous for a mutant LPL allele have been described with chylomicronemia and increased VLDL (type V), increased VLDL alone (type IV), increased LDL (type IIA), or increased VLDL and LDL (type IIB) (7, 9, 10) . Reduced HDL cholesterol concentrations have been observed regularly among hypertriglyceridemic relatives. These observations led to the suggestion (6, 7) that the phenotype resulting from the carrier genotype is familial combined hyperlipidemia (1 1).
Heterozygotes for LPL deficiency have escaped unambiguous identification. In obligate carriers mean adipose tissue LPL activities are reduced -50% (5), but individual measurements overlap with normal (7) . Suspected carriers likewise may have reduced or normal postheparin plasma LPL activities by selective assay (1). Babirak and co-workers (6) assayed immunoreactive LPL (12) (13) (14) along with postheparin plasma LPL activity to identify nonobligate carriers in small kindreds.
We previously described a patient with classical LPL deficiency (type I) along with data from 47 relatives in her large nonconsanguineous pedigree (7) . When she was first studied at age 19 , postheparin plasma and adipose tissue LPL activities were at the limits of detection. Apo C-II was present on polyacrylamide gel electrophoresis and normal LPL cofactor activity was detected (7) . Plasma lipids and lipoproteins were entirely normal in the proband's father and the paternal lineage. Her mother had Type IV hyperlipoproteinemia, and some members of the maternal lineage exhibited hypertriglyceridemia, intermittent fasting chylomicronemia, elevated VLDL cholesterol, and/or decreased HDL cholesterol concentrations. Three individuals in the pedigree had calculated LDL cholesterol concentrations that exceeded 95th percentile age-and sex-specific cutoffs. Whether the multiple lipoprotein patterns observed in relatives of the proband resulted from heterozygous LPL deficiency or from the fortuitous, independent oc-opened the way for genetic characterization of probands with clinical LPL deficiency (16) (17) (18) . By cloning and sequencing cDNA prepared from adipose tissue total RNA isolated in the proband, we have found that she was homozygous for a single point mutation (GGG-*iGAG) at position 818 of the LPL cDNA leading to a glycine-to-glutamic acid substitution at residue 188 of the mature enzyme (18) . Furthermore, in vitro expression of the mutant gene resulted in the production of immunoreactive but functionally defective LPL (18) . Profound deficiency of postheparin plasma LPL activity in the proband (7) was confirmed independently, and immunoreactive material was detected in postheparin plasma with a specific ELISA.
Knowing the molecular defect in the proband in the present study, it became possible to determine directly the carrier status of family members with respect to this mutation and to investigate phenotypic expression of the mutation in the heterozygous state.
Methods
Experimental subjects. K2003 is nonconsanguineous, Caucasian, and of mostly Northern European descent. Both of the proband's grandfathers died before age 65 with a history of heart disease. The maternal grandmother died at 82 of unknown causes. The paternal grandmother, 81 yr old at the time ofour previous study, died in the interim. The proband's father has developed non-insulin-dependent diabetes mellitus. He received a pacemaker for cardiac arrhythmia in 1989 but he did not have significant coronary artery disease by angiography.
Most of the 47 family members originally ascertained between 1978 and 1981 consented to be restudied. Additional subjects from the extended pedigree, including spouses, were recruited randomly in the absence of information about their lipid or lipoprotein profiles, and initially without knowledge of parental or sibling carrier status. Later, as the carrier status of members of the pedigree became known, the offspring of carriers were actively recruited. In toto, 126 subjects were sampled, excluding the index patient. All subjects completed a targeted questionnaire, had body height, weight, and blood pressure measured, and gave informed consent according to institutional guidelines.
Laboratory analyses. Venous blood samples were collected after subjects had fasted 12-15 h according to Lipid Research Clinic guidelines (19) . Plasma lipids were characterized by a microprocedure described elsewhere (20) . The VLDL were separated from other lipoproteins by room temperature ultracentrifugation of200 M1 ofplasma for 4 h at 60,000 rpm in a tabletop centrifuge (model TL-l00; Beckman Instruments, Fullerton, CA). Cholesterol in the HDL fraction was measured after MgCl2-dextran sulfate precipitation (21) . LDL ., subject proven to be a carrier with allele-specific oligonucleotide E 10-probes; o, noncarrier; @,living subject, not studied; a , deceased Z subject, not studied.
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(Inset) Subjects age 40 or older. 4.- In the multivariate analysis (Table III) (Table II) most of these associations disappeared in the multivariate analysis (Table III) . Thus, neither alcohol nor antihypertensive use could account for the observed differences between carriers and noncarriers.
Obesity and related conditions. Familial hypertriglyceridemia with or without fasting chylomicronemia is often associated with obesity, hypertension, hyperglycemia, hyperinsulinemia, and hyperuricemia (25, 27, 28) . It is not known whether these associations are genetically determined, or due to lifestyle and environmental factors. Ofthe eight instances of non-insulin-dependent diabetes, six occurred in noncarriers and 2 (003 and 384) among carriers (Appendix and Table V) . Thus, the prevalence of hyperglycemia and overt diabetes was no different between carriers and noncarriers, nor increased from the known prevalence of diabetes in the general population.
No statistically significant differences were found by univariate analysis between noncarriers and carriers in mean age, blood glucose, serum insulin, or body mass index (Table VI) . However, serum uric acid was increased (P = 0.018) and blood pressure tended to be higher in older carriers. Hypertriglyceridemic carriers and noncarriers were older, more obese, more hyperglycemic, hyperinsulinemic, hyperuricemic, and hypertensive than normotriglyceridemic subjects of the same genotype (Table VII) . As expected, these variables proved highly interdependent. Plasma insulin concentration rose with increasing body mass index both in normals and carriers (P = 0.0001 and P = 0.0005, respectively; Kendall's r corrected for ties). Similarly plasma triglyceride concentration correlated with body mass index (P = 0.0001 and P = 0.001; analyses not shown) and with plasma insulin (P = 0.0001 and 0.003) in noncarriers and carriers, respectively (Fig. 7) . Weaker negative correlations were also found between HDL cholesterol and plasma insulin or body mass index (P = 0.02-0.05; analyses not shown). Thus, conditions previously shown to be associated with familial hypertriglyceridemia were also associated with the expression of heterozygous LPL deficiency in this pedigree. Separate multivariate analyses with the candidate variables showed systolic and diastolic blood pressure and uric acid to be associated with age and body mass index (Table VIII) . Serum insulin concentration was associated with body mass index alone. A marginally significant independent contribution of age * carrier status to systolic blood pressure was observed even though subjects were receiving concurrent antihypertensive treatment. Although the latter observation might suggest that the mutant allele predisposes to hypertension, this conclusion is highly tentative since the number of affected carriers was small.
To further illustrate phenotypic differences between noncarriers and carriers, discriminant analysis was performed using carrier status as the grouping variable (Table IX) . The discriminating variables chosen for testing were the plasma lipid and lipoprotein variables as well as other variables that might vary with carrier status. In the analysis, the strongest predictor of carrier status was plasma triglyceride concentration, followed by LDL cholesterol, and apoB. These three variables, which ostensibly reflect unique features of lipoprotein metabolism in the heterozygous state, correctly predicted carrier status in 83% of all analyzed cases.
Adipose tissue LPL activity. Knowledge of the LPL genotype in 14 (7 carriers and 7 noncarriers) of the 19 subjects previously studied in 1981 (7) permitted retrospective analysis of the ability of adipose tissue LPL activity to discriminate between carriers and noncarriers (Fig. 8) . Mean 
Discussion
We have studied the extended pedigree ofa proband with type I hyperlipoproteinemia shown to be homozygous for a missense mutation in the lipoprotein lipase gene. This pedigree, notable for its size and lack of consanguinity as well as a low incidence ofpremature coronary artery disease and confounding variables such as alcohol abuse or tobacco use in living members (Table V) , provided a unique opportunity to clarify the phenotype associated with heterozygous LPL deficiency. Carriers and noncarriers were identified by hybridization of enzymatically amplified DNA with allele-specific oligonucleotide probes. Genotyping proved essential since adipose tissue LPL activities, determined in a previous study (7) and examined retrospectively, did not detect proven carriers reliably.
The phenotype associated with heterozygous LPL deficiency in this pedigree was characterized by hypertriglyceridemia, elevated VLDL cholesterol, and low LDL and HDL cholesterol concentrations (type IV hyperlipoproteinemia), occurred together with well-recognized predisposing factors, and was transmitted in an autosomal codominant pattern. Hypertriglyceridemia in carriers proved to be strongly age dependent. Variable expression associated with age or age-related factors resulted in incomplete penetrance. Only 40% ofproven carriers exhibited the abnormal phenotype. Thus, 94% of young carriers had normal triglyceride concentrations, (71) Noncarriers (54) 7.4 (4) 3.7 (2) Carriers (17) 11.8 (2) 0.0 (0) Age 2 40 yr (55) Noncarriers (43) 20.9 (9) 14.0 (6) Carriers (12) 25.0 Carriers (29) 10.3 (3) -6.9 (2) Age < 40 yr (71) Noncarriers (54) 11.1 (6) 7.4 (4) Carriers (17) 11 Although hypertriglyceridemia, low HDL, and low LDL segregated with the mutant allele, a number of noncarriers exhibited similar abnormalities. Phenotypic differences be-not the number, of HDL particles is altered in heterozygous LPL deficiency.
In contrast to HDL cholesterol, which decreased with hypertriglyceridemia in both carriers and noncarriers, LDL cholesterol fell significantly in carriers only. Several mechanisms might be involved including reduced lipolytic conversion of VLDL to LDL, exchange of triglyceride for free cholesterol between VLDL and LDL, or a shift in the density distribution of triglyceride-enriched LDL particles (33) . Whichever mechanism is responsible, the LDL/HDL ratio, used widely to predict atherogenic risk, was significantly correlated with plasma triglyceride concentration only in noncarriers. tween carriers and noncarriers were subtle. Decreased HDL cholesterol, a regular finding in hypertriglyceridemia of any cause (29), was present in both hypertriglyceridemic carriers and noncarriers in this study but was more pronounced in the former (Table I) Obesity, hypertension, hyperuricemia, hyperinsulinemia, mild hyperglycemia, and low HDL were all observed in hypertriglyceridemic members of kindred 2003 who were thus representative of subjects with primary hypertriglyceridemia (27, (34) (35) (36) (37) . LPL activity (38) (39) (40) has correlated directly with plasma triglyceride concentration, inversely with in vivo measures of triglyceride disposal (39) , and is affected by insulin (41) (42) (43) (44) , aging, and obesity (38, 39) . In addition, a significant number of hyperlipidemic subjects were receiving estrogens, thiazides, and beta-adrenergic blocking drugs despite the wellknown propensity of these agents to perturb plasma lipid and lipoprotein metabolism.
Although techniques to study triglyceride kinetics have evolved significantly (45, 46) , older studies clearly indicate that VLDL-TG production is highly correlated with body weight and fasting serum insulin concentration (47) . Despite this prominent effect of obesity on VLDL production, maximum heparin-releasable plasma LPL activity fails to increase in obese normotriglyceridemic subjects (48) . The complex interrelationships between hypertriglyceridemia and aging, obesity, insulin resistance, hyperinsulinemia, and carbohydrate intolerance have been studied intensively, yet a primary metabolic abnormality has not been accepted universally. There is experimental evidence that hyperfattyacidemia interferes with glucose disposal, increases plasma glucose concentrations, and thereby leads to hyperinsulinemia (49-52). Thus hyperinsulinemia in obesity (53) could be an epiphenomenon, rather than an independent determinant of VLDL-TG production rate (54, 55). Regardless of the underlying mechanism, heterozygous LPL deficiency and obesity would be expected to be cooperative in the pathogenesis of hypertriglyceridemia.
This study provides independent support for the proposal (45, 56, 57 ) that a subset of patients with primary hypertriglyceridemia has an underlying inherited defect in triglyceride-rich lipoprotein removal consequent to impaired LPL function. Decreased LPL activity has been found in many (38, 39, 58, 59 ) but not all (34, 60) studies of patients with primary hypertriglyceridemia. Genetic defects in LPL, unrecognizable without specific probes for mutant alleles, might account for kinetic heterogeneity as well (57, 61) . Decreased Multivariate analysis was performed as described in the legend to Table III. (61-68) but not all (69, 70) studies. Although obesity regularly leads to VLDL-TG overproduction, overweight subjects do not necessarily become hypertriglyceridemic if their TG clearance rates increase (62); other obese subjects without an increase in clearance become hypertriglyceridemic, consistent with heterogeneity in the efficiency of triglyceride catabolism. Defective VLDL catabolism can be familial in subjects selected for primary hypertriglyceridemia. Thus, defective removal along with reduced postheparin LPL activity was found in older subjects with "poorly classified" familial hypertnglyceridemia (65) . Sane and Nikkila (68) found decreased FCR along with increased production in index subjects in whom coexisting defects in removal and production would be expected if overt hypertriglyceridemia requires increased lipoprotein synthesis. However, decreased FCR was the only ki- Discriminant analysis was performed using carrier status as the grouping variable. The log-transformed discriminating variables, systolic blood pressure, diastolic blood pressure, uric acid, insulin, apo A-I, apo B, and age-sex adjusted triglyceride, VLDL cholesterol, LDL cholesterol, and HDL cholesterol, were included by a stepwise selection procedure with the smallest Wilks' lambda as the selection criterion. F-to-enter and F-to-remove were set at 3.5 and 2.5, respectively. Default values were used for all other settings. The resulting discriminant function, which retained the predictor variables triglyceride, LDL cholesterol and apo B in the order mentioned, classified 83.3% of all analyzed cases correctly, assuming equal prior probability of belonging to either group.
netic abnormality segregating among the first-degree relatives of probands with a low VLDL-TG FCR (68) . Thus, our findings are consistent with the hypothesis that carriers become hypertriglyceridemic when VLDL production saturates (71, 72 ) the capacity of LPL to hydrolyze VLDL triglyceride; theoretically this can result from an increase in VLDL production, from LPL downregulation, or both. Such a mechanism might also explain why young homozygotes, with presumably normal or low rates of VLDL synthesis, have hyperchylomicronemia in the absence ofelevated plasma VLDL (73), whereas older heterozygous carriers exhibit increased plasma VLDL concentrations. Subjects with rare inherited metabolic disorders are often found to be compound heterozygotes at a molecular level (74) . One must therefore anticipate pedigrees of LPL-deficient probands manifesting distinct allelic mutations, and others with clinically important interactions between mutant LPL genes and common non-allelic hyperlipidemia genes. Thus, if heterozygous LPL deficiency were to segregate independently along with a gene directing increased VLDL apo B synthesis, the phenotype observed in a pedigree might resemble familial combined hyperlipidemia. Whether other mutations in the LPL gene will result in clinically distinct phenotypes, or what the outcome will be of interactions of mutant LPL alleles with other more common hyperlipidemia genes remains to be investigated.
In summary, findings in this pedigree underscore the complex interactions between genetic and environmental factors that lead to hypertriglyceridemia. Heterozygosity for a mutation in the LPL gene was an important precondition for familial hypertriglyceridemia. Nevertheless, a number of noncarriers exhibited a nearly identical phenotype as they became older and heavier, and were exposed to lipid-raising drugs. Conversely pertriglyceridemic subjects with combined defects in triglycerHeterozygous LPL deficiency usually led to a latent abnoride metabolism (56, 61) .
